Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04562129

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

Sponsor: Clinigen, Inc.

Conditions Inoperable Disease Melanoma Stage III Melanoma Stage IV

Interventions Interleukin-2 Ipilimumab Nivolumab

Updated 24 times since 2020 Last updated: Jan 27, 2026 Started: Sep 24, 2020 Primary completion: Jul 31, 2026 Completion: Nov 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04562129, this PHASE2 trial focuses on Inoperable Disease and Melanoma Stage III and remains actively recruiting participants. Sponsored by Clinigen, Inc., it has been updated 24 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

24 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Jul 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE2

▶ Show 19 earlier versions

Nov 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Mar 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Jan 2023 [monthly]

Recruiting PHASE2
May 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Dec 2021 — May 2022 [monthly]

Recruiting PHASE2
Sep 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Apr 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE2
Oct 2020 — Nov 2020 [monthly]

Recruiting PHASE2

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinigen, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States